Serologicals Corporation has entered into a multi-year agreement with Cangene Corporation to provide hyperimmune plasma for use in the manufacturing of vaccinia immune globulin (VIG), to be used in treating and preventing severe reactions that may be brought on by the administration of the smallpox vaccine.

All of the Company's' specialty plasma collection centers throughout the United States are participating in this program, which will collect plasma from re-vaccinated donors in order to manufacture the globulin, which is the only product that can be used to treat the complications of vaccination with the smallpox vaccine.

"We are excited about this expansion of our hyperimmune plasma business, which is consistent with our strategic objective of adding increased shareholder value from this important segment of our business. As the recognized leader in providing hyperimmune plasma, Serologicals Corporation continues to evaluate new and expanded opportunities in similar areas," said David A. Dodd, President and Chief Executive Officer for Serologicals Corporation.